Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralatrexate and Docetaxel in Advanced Esophageal and Gastroesophageal Carcinoma
NCT01129206Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jul 2010
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pralatrexate in esophageal cancer, gastroesophageal junction cancer, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Jul 2010; status: completed.
02
Drugs
pralatrexate
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT01129206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01129206.